Inovio Pharmaceuticals (NASDAQ:INO) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $1.95 and traded as high as $2.25. Inovio Pharmaceuticals shares last traded at $2.14, with a volume of 1,814,162 shares.

Analyst Upgrades and Downgrades

INO has been the topic of several recent analyst reports. Oppenheimer decreased their price objective on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, May 14th. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 27th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th. Finally, HC Wainwright reiterated a “neutral” rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $9.75.

Inovio Pharmaceuticals Price Performance

The stock’s fifty day moving average price is $2.01 and its 200-day moving average price is $1.95. The firm has a market cap of $78.47 million, a PE ratio of -0.67 and a beta of 1.31.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.23. The business had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.01 million. On average, sell-side analysts anticipate that Inovio Pharmaceuticals, Inc. will post -4.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Barclays PLC boosted its holdings in Inovio Pharmaceuticals by 15.0% in the 4th quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,111 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares during the period. Geode Capital Management LLC lifted its holdings in Inovio Pharmaceuticals by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after acquiring an additional 6,874 shares during the last quarter. Northern Trust Corp grew its position in Inovio Pharmaceuticals by 6.4% in the fourth quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company’s stock worth $401,000 after acquiring an additional 13,269 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Inovio Pharmaceuticals by 22.4% in the first quarter. Bank of New York Mellon Corp now owns 75,422 shares of the biopharmaceutical company’s stock worth $123,000 after acquiring an additional 13,784 shares during the period. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.